Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28225986 | 1.00 | CXCR4 (0.39) | CXCR4PDE4AMAPK1PDE4DPDE4B | |
| SCHEMBL28225984 | 1.00 | CXCR4 (0.39) | CXCR4PDE4AMAPK1PDE4DPDE4B | |
| SCHEMBL29452904 | 1.00 | CXCR4 (0.39) | CXCR4PDE4AMAPK1PDE4DPDE4B | |
| SCHEMBL21187236 | 0.86 | HTR2A (0.32) | CXCR4PDE4AMAPK1PDE4DPDE4B | |
| SCHEMBL21176974 | 0.81 | GPR84 (0.34) | NAAADDB1CRBNGPR84HTR2A | |
| SCHEMBL21176977 | 0.81 | GPR84 (0.34) | NAAADDB1CRBNGPR84HTR2A | |
| SCHEMBL29452916 | 0.81 | GPR84 (0.34) | NAAADDB1CRBNGPR84HTR2A | |
| SCHEMBL28226023 | 0.79 | HRH3 (0.40) | NAAAHTR2A | |
| SCHEMBL28226022 | 0.79 | HRH3 (0.40) | NAAAHTR2A | |
| SCHEMBL29452874 | 0.79 | CXCR4 (0.33) | CXCR4PDE4AMAPK1PDE4DPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | claimed |
| US-12545653-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2019141229-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | 上海怡立舍生物技术有限公司 | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545653-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARD, PPARG | CXCR4 1089/4885PDE4A 559/4885MAPK1 2039/4885 |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARG, PPARD | CXCR4 722/4885PDE4A 236/4885MAPK1 2533/4885 |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | CXCR4 722/4885PDE4A 236/4885MAPK1 2533/4885 |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | CXCR4 722/4885PDE4A 236/4885MAPK1 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.